Bacteriophages therapy in otorhinolaryngology. History and contemporaneity

Close metadata

Bacterial infections of the upper respiratory tract in the structure of the incidence of the population ranked second. Recently in practice there are more and more cases of a protracted course of the disease, chronic inflammation, as well as various kinds of complications. The abuse and misuse of antibiotics has contributed to the growth of antibiotic-resistant bacterial strains. This problem is named one of the most pressing for public health in the world. In this regard, the topical issue is the search for alternative drugs foe treating infectious diseases. Bacteriophage preparations that have a 100-year history and have gone a long way in development have shown their effectiveness as an alternative to antibiotics, and as an additional therapy in the treatment of certain bacterial infections. This review includes data from various studies available in English, as well as the results of domestic reports published in Russian scientific literature.

Keywords:

bacteriophage preparations

Authors:

Krukov A.I.

Sverzhevsky Moscow Scientific and Practical Othorhinolaryngology Center, Moscow

Gurov A.V.

Kafedra otorinolaringologiiRNIMU im. N.I. Pirogova Minzdravsotsrazvitiia Rossii, Moskva

Izotova G.N.

Moskovskiĭ nauchno-prakticheskiĭ tsentr otorinolaringologii im. L.I. Sverzhevskogo Departamenta zdravookhraneniia, Moskva, Rossiia, 117152

Lapenko E.G.

L.I. Sverzhevskiy Research Institute of Clinical Otorhinolaryngology, Moscow Health Department, Moscow, Russia, 117152

List of references:

Krukov AI, Turovsky AB. Etiotropic therapy of bacterial sinusitis. Consilium Medicum. 2005;7(1):7-10. (In Russ.)
Palchun VT, Luchihin LA. The expediency and effectiveness of antibiotic therapy in ENT practice. Vestnik otorinolaryngologii. 2006;3:27-30. (In Russ.)
Centers for Disease Control and Prevention Get smart: know when antibiotics work. 2014. http://www.cdc.gov/getsmart/healthcare/
Summers WC. Felix d’Herelle and the Origins of Molecular Biology. Yale University Press. 1991;85-90.
Bruynoghe R, Maisin J. Essais de the’rapeutique au moyen du bacteriophage. C R Soc Biol. 1921;1120-1121.
Tsulukidze AP. Phage treatment in surgery. Surgery («Khirurgia»). 1940;12:132-133. (In Russ.)
Kokin GA. Use of bacteriophages in surgery. Sov Med. 1941;9:15-18. (In Russ.)
Krestovnikova VA. Phage treatment and phage prophylactics and their approval in the works of the Soviet researchers. J Microb Epidemiol Immunol. 1947;11:56-65. (In Russ.)
Weber-Dabrowska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: an update of our institute’s experience. Arch Immunol Ther Exp. 2000;48:547-551. https://doi.org/10.1007/978-94-015-9702-9_15
Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob agents chemother. 2001;45:649-659. https://doi.org/10.1006/rwgn.2001.0981
Chanishvili NA. Literature Review of the Practical Application of Bacteriophage Research. New York: Nova Science Publishers; 2009.
Górski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs. 2009;10:766-774.
Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Szufnarowski K. Clinical aspects of phage therapy. Adv Virus Res. 2012;83:73-121. https://doi.org/10.1016/B978-0-12-394438-2.00003-7
Jukov-Verejnikov NN, Peremitina LD, Berilo EA i dr. Study of therapeutic effect of bacteriophage preparations in complex treatment of purulent surgical diseases. Sov med. 1978;12:64-66. (In Russ.)
Bogovazova GN, Voroshilova NM, Bondarenko VM. The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection. Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 1991;4:5-8. (In Russ.)
Brusov PG, Zubritsky VF, Islamov RN, Nizovoi AV, Fominyh EM. Phagoprofilaxis and phagotherapy of surgical infections. Military medical journal. 2011;4:34-39. (In Russ.)
Morozova VV, Vlassov VV, Tikunova N. Applications of Bacteriophages in the Treatment of Localized Infections in Humans. Frontiers in Microbiology. 2018;9:1696. https://doi.org/10.3389/fmicb.2018.01696
Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013;8:6:769-783. https://doi.org/10.2217/fmb.13.47
Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009;18:240-243. https://doi.org/10.12968/jowc.2009.18.6.42801
Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34:349-357. https://doi.org/10.1111/j.1749-4486.2009.01973.x
Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care. 2016;25:27-33. https://doi.org/10.12968/jowc.2016.25.7.S27
Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care. 2017;21:129. https://doi.org/10.1186/s13054-017-1709-y
Preobragensky NA, Goldman II, Lipkin AI. The problem of conservative treatment of patients with chronic purulent otitis media. Vestnik Otorinolaryngologii. 1982;2:18-20. (In Russ.)
Krivohatskaya LD, Cheremkin AS. About the possibility of increasing the bacteriolytic activity of pseudomuscular bacteriophage in chronic purulent otitis media. J of ear, nose and throat deseases. 1984;5:55-58. (In Russ.)
Volosevich LL, Krivohatskaya LD, Chemerkin AS. The effectiveness of the use of therapeutic bacteriophages in patients with chronic suppurative mesotympanitis. J of ear, nose and throat deseases. 1985;3:55-59. (In Russ.)
Bogovazova GG, Voroshilova VM, Bondarenko NN. Immunobiological properties and therapeutic efficacy of Klebsiella bacteriophage. J microbiol epidem immunobiol. 1992;3:30-33. (In Russ.)
Sakandelidze VM. The combined use of specific phages and antibiotics in different infectious allergoses. Vrach Delo. 1991;3:60-63. (In Russ.)
Weber-Dabrowska B, Kozminska J, Mulczyk M, Kaczkowski H. Wykorzystanie bakteriofagow w leczeniu przewleklego ropnego — zapalenia zatok szczekowych. Post Med Klin Dosw. 1996;5:3:291-293.
Sultanov NM. Antibacterial activity and clinical efficacy of a polyvalent purified pyobacteriophage preparation for the treatment of chronic purulent rhinosinusitis: Dis... kand. biol. nauk. 2007. (In Russ.)
Anikina TA, Ryazanova SKh, Sergeeva EN. Freshly isolated pathogen strains are the most important component of the production of adapted therapeutic and preventive bacteriophages. Vaccinology. 2006;3. (In Russ.)
Stratieva OV. Use of polyvalent combined pyobacteriophage in acute and recurrent paranasal sinusitis in children. Col. of proceedings of the XV congress of otolaryngologists of Russia. 1995;2:32-35. (In Russ.)
Yanborisova ER, Yanborisov TM. Effect of pyobacteriophage on mucociliary clearance when applied topically in children with acute sinusitis. Russian rhinology. 1997;2:55. (In Russ.)
Drilling A, Btech B, Morales S, Hons MSc, Jardeleza C. Bacteriophage Reduces Biofilm of Staphylococcus Aureus Ex Vivo Isolates from Chronic Rhinosinusitis Patients. Amer J of Rhinology & Allergy. 2014;28(1):3-11. https://doi.org/10.2500/ajra.2014.28.4001
Speck PG, Wormald P-J. Is phage therapy suitable for treating chronic sinusitis Staphylococcus aureus infection? Future Microbiol. 2018;13(6):605-608. https://doi.org/10.2217/fmb-2017-0264
Fong SA, Drilling A. Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients. Front Cell Infect Microbiol. 2017;7:418. https://doi.org/10.3389/fcimb.2017.00418
Drilling AJ, Ooi ML, Miljkovic D, Craig J, Speck P, Vreugde S, Clark J, Wormald P-J. Long-Term Safety of Topical Bacteriophage Application to the Frontal Sinus Region. Frontiers in Cellular and Infection Microbiology. 2017;24:7-49. https://doi.org/10.3389/fcimb.2017.00049
Murphy T, Lewin A, Parker-Athill C, Storch E. Tonsillectomies and Adenoidectomies Do Not Prevent the Onset of Pediatric Autoimmune Neuropsychiatric Disorder Associated With Group A Streptococcus. Pediatr Infect Dis J. 2013;32(8):834-838. https://doi.org/10.1097/INF.0b013e31829062e2
Hudonogova ZP, Evstropov AN, Vasilyeva NG i dr. The effectiveness of the use of staphylococcal bacteriophage in the topical therapy of chronic tonsillitis. Russian otorhinolaryngology. 2011;6:55:175-180. (In Russ.)
Zaripova TN, Mukhina VI, Chuykov KN. The rationale for the use of bacteriophage in the treatment of patients with acute exacerbation of chronic laryngitis — persons with golovorotevye professions. Otolaryngology. 2013;14:1008-1014. (In Russ.)
Kim KP, Cha JD, Jang EH. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb Biotechnol. 2008;1:247-257. https://doi.org/10.1111/j.1751-7915.2008.00028.x
Vitiello CL, Merriln CR, Adhya S. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. Virus Res. 2005;114:101-103. https://doi.org/10.1016/j.virusres.2005.05.014
Yoichi M, Abe M, Miyanaga K, et al. Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. J Biotechnol. 2005;115(1):101-107. https://doi.org/10.1016/j.jbiotec.2004.08.003
Pouillot F, Blois H, Iris F. Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. Biosecur Bioterror. 2010;8:155-169. https://doi.org/10.1089/bsp.2009.0057
Mahichi F, Synnott AJ, Yamamichi K, et al. Site-specific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity. FEMS Microbiol Lett. 2009;295:211-217. https://doi.org/10.1111/j.1574-6968.2009.01588.x
Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA. 2001;27:98:7:4107-4112. https://doi.org/10.1073/pnas.061038398
Paul VD, Sundarrajan S, Rajagopalan SS, et al. Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol. 2011;11:195. https://doi.org/10.1186/1471-2180-11-195
Catalao MJ, Moniz-Pereira J. Diversity in bacterial lysis systems: bacteriophages show the way. FEMS Microbiol Rev. 2013;4:554-571. https://doi.org/10.1111/1574-6976.12006
Bruttin A, Brussow H. Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy. Antimicrobial Agents and Chemotherapy. 2005;49:7:2874-2878. https://doi.org/10.1128/aac.49.7.2874-2878.2005
Górski A, Jończyk-Matysiak E, Łusiak-Szelachowska M, Międzybrodzki R, Weber-Dąbrowska B, Borysowski J. Phage therapy in allergic disorders? Experimental Biology and Medicine. 2018;243:6:534-537. https://doi.org/10.1177/1535370218755658
Arefieva NA, Aznabayeva LF, Voroshilova NN, Sultanov NM. Comparative study of the effects of treatment methods on the local immunity condition of the nasal mucous membranes in patients with chronic purulent rhinosinusitis. Basic research. 2007;4:7-10. (In Russ.)
Pagava KI, Gachechiladze KK, Korinteli IA, Dzuliashvili MG, Alavidze ZI, Hoyle N, Metskhvarishvili GD. What happens when the child gets bacteriophage per os. Georgian Med News. 2011;196-197:101-105.

Close metadata